Drug makers accuse V Mohan of possible conflict of interest in getting diabetes drug Pioglitazone banned

Bhushan Pundlik Shirude

In January this year, Mohan had written a letter to the Prime Minister’s Office, detailing the risks of bladder cancer caused by the prolonged use of
In January this year, Mohan had written a letter to the Prime Minister’s Office, detailing the risks of bladder cancer caused by the prolonged use of

MSD Pharma, on its defence, has said that the company follows the highest standards of ethics, compliance and regulations, which take precedence over business without any compromise. “Our support to CCEBDM(Certificate Course in Evidence BasedDiabetes Management) is in line with our philosophy of putting patients above all else. This multi-stakeholder programme is being managed by Public Health Foundation of India (PHFI) in association with Mohan’sDiabetes Education Academy, and is successfully addressing the much required capacity development needs among general physicians in the country for a rapidly growing disease like type 2 diabetes.

MSD strongly denies any allegations regarding this programme which have recently appeared in some sections of the media,” said an MSD…

View original post 70 more words


Silos in Drug Development

The Next Element

I was in Chicago last month for the American Society of Clinical Oncology (ASCO) annual meeting where as you would expect the topic of conversation was cancer at every turn. While it is generally easy to get wrapped up in these conversations, this year was different. Just a couple of weeks before the meeting, I lost someone very special to me who had been undergoing treatment for cancer. 

While some people come to drug development searching for a solution for someone they care about, my journey had been more about intellectual curiosity than passion. In my training as a chemist, my emotions generally involved frustration with reactions that wouldn’t work or elation when a multi-step synthesis resulted in the molecule I was trying to make. When I moved away from the bench, I took on the alternate responsibilities and tasks associated with clinical development, which eventually included reviewing case report…

View original post 416 more words

Pfizer’s Xeljanz approved in Switzerland, first European country to approve the drug

July 15 2013 | By Márcio Barra

Pfizer just issued a press release where it reports that Switzerland’s SwissMedic has approved its rheumatoid arthritis treatment Xeljanz (tofacitinib citrate) for sale. This makes Switzerland the first European country to approve Xeljanz for adult patients with moderate-to-severe active RA who had an inadequate response or intolerance to the antirheumatic agent methotrexate.

View original post 273 more words

Hypertension- Maybe Your Blood’s too Thick

Medical Revolt


While watching the documentary Forks Over Knives I heard a physician explain that it was possible that a vegan diet may lower blood pressure by lowering the blood viscosity (thickness). He stated this in passing but to me it was earth-shaking. I have had thousands of patients with high blood pressure and am treating it on a daily basis. I have sat through countless lectures on hypertension and still to this day we do not really know what causes it. The leading explanations include increased sympathetic activity (think high adrenaline, anxiety), decrease kidney function with age, increased hormone called angiotensin II, or complex interaction of genetic factors. However all of these fail to really explain why obesity, inactivity and diet raise blood pressure.

When I heard that it could be the viscosity (thickness) of the blood I was overwhelmed by the simplicity of it. If the blood is thicker it…

View original post 651 more words

Alkermes unveils three new drug candidates

New Drug Approvals

Alkermes has unveiled three new drug candidates, including: a monomethyl fumarate (MMF) prodrug programme for the treatment of multiple sclerosis; ALKS 7106 for the treatment of pain; and RDB 1419, a cancer immunotherapy candidate based on interleukin-2 (IL-2) and its receptors, Alkermes’ first proprietary biologic.

According to Alkermes, these drug candidates demonstrate the company’s focus on unmet medical needs in specific patient populations and show the productivity of its expanded R&D capabilities.

read all at






View original post